Biocytogen Pharmaceuticals (Beijing) Co Ltd Class H 02315
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if 02315 is a good fit for your portfolio.
News
Trading Information
- Previous Close Price
- HKD 8.90
- Day Range
- HKD 8.61–8.83
- 52-Week Range
- HKD 5.74–25.25
- Bid/Ask
- HKD 8.78 / HKD 8.80
- Market Cap
- HKD 3.50 Bil
- Volume/Avg
- 150,500 / 170,095
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 4.37
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- 0.26%
Company Profile
Biocytogen Pharmaceuticals (Beijing) Co Ltd is a biopharmaceutical and pre-clinical research services company. It has two Core Products, YH003 and YH001. YH003 is a recombinant humanized agonistic anti-Cluster of Differentiation 40 (CD40) Immunoglobulin G2 (IgG2) monoclonal antibody and YH001 is a recombinant humanized anti-CTLA-4, a protein receptor expressed constitutively on T cells that functions as an immune checkpoint and downregulates immune responses, Immunoglobulin G1 (IgG1) monoclonal antibody. YH003 is being developed for pancreatic ductal adenocarcinoma, melanoma and other advanced solid tumors. YH001 is being developed for hepatocellular carcinoma (HCC), non-small-cell lung carcinoma (NSCLC) and other solid tumors.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 1,066
- Website
- https://www.biocytogen.com.cn
Comparables
Valuation
|
Metric
|
02315
|
02480
|
688382
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 4.00 | 5.04 | 2.91 |
Price/Sales | 4.37 | — | 29.20 |
Price/Cash Flow | — | — | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
02315
|
02480
|
688382
|
|---|---|---|---|
Quick Ratio | 1.02 | 13.22 | 14.92 |
Current Ratio | 1.30 | 13.27 | 14.99 |
Interest Coverage | −5.27 | −200.71 | — |
Quick Ratio
02315
02480
688382
Profitability
|
Metric
|
02315
|
02480
|
688382
|
|---|---|---|---|
Return on Assets (Normalized) | −13.53% | −14.55% | −11.04% |
Return on Equity (Normalized) | −37.28% | −16.16% | −11.80% |
Return on Invested Capital (Normalized) | −20.22% | −16.01% | −13.23% |
Return on Assets
02315
02480
688382
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Jqdcnlsqf | Kynz | $559.7 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Rkdhxffb | Wbvhbc | $103.9 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Twhrqtss | Tbgrb | $103.3 Bil | |
MRNA
| Moderna Inc | Xxjnqyfh | Ylbxp | $42.7 Bil | |
ARGX
| argenx SE ADR | Vtgzwwm | Zpgl | $22.2 Bil | |
BNTX
| BioNTech SE ADR | Vwdzwndyc | Jjh | $21.7 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Dbzprcy | Fqjtghd | $19.0 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Fcbrwsx | Sphmglh | $15.8 Bil | |
RPRX
| Royalty Pharma PLC Class A | Ltcvyxxjz | Rlndnlb | $12.7 Bil | |
INCY
| Incyte Corp | Vkfnqzxw | Xwvwkh | $11.9 Bil |